Myelodysplastic Syndrome Clinical Trial
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
Summary
The purpose of this study is to enable continued access to zilucoplan (RA101495) for patients with paroxysmal nocturnal hemoglobinuria (PNH) after they complete a zilucoplan clinical study.
Eligibility Criteria
Inclusion Criteria:
Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan (RA101495) PNH study
Evidence of ongoing clinical benefit in the opinion of the Investigator
Exclusion criteria:
History of meningococcal disease
Current systemic infection or suspicion of active bacterial infection
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
Los Angeles California, 90033, United States
Dallas Texas, 75390, United States
Gosford , , Australia
Melbourne , , Australia
Toronto , , Canada
Helsinki , , Finland
Ulm , , Germany
Budapest , , Hungary
Christchurch , , New Zealand
Hamilton , , New Zealand
Leeds , , United Kingdom
London , , United Kingdom
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.